Placebo + Pimavanserin 34 mg + Pimavanserin 20 mg
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dementia-related Psychosis
Conditions
Dementia-related Psychosis
Trial Timeline
Sep 27, 2017 → Oct 30, 2019
NCT ID
NCT03325556About Placebo + Pimavanserin 34 mg + Pimavanserin 20 mg
Placebo + Pimavanserin 34 mg + Pimavanserin 20 mg is a phase 3 stage product being developed by Acadia Pharmaceuticals for Dementia-related Psychosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03325556. Target conditions include Dementia-related Psychosis.
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03325556 | Phase 3 | Completed |